Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
暂无分享,去创建一个
S Michiels | M Buyse | S Marguet | M. Buyse | M. Piccart | F. Penault-Llorca | S. Michiels | D. Cameron | V. Nekljudova | S. Johnston | G. von Minckwitz | C. Vogel | M. Cobleigh | A. Leo | G. Gasparini | M. Marty | S. Marguet | S. Paluch-Shimon | B. Kaufman | A. Di Leo | G. Minckwitz | D. Slamon | G Gasparini | D Cameron | M Piccart | J. Barinoff | J Barinoff | G von Minckwitz | A Di Leo | F Penault-Llorca | L Pugliano | D Grun | M Cobleigh | S Johnston | B Kaufman | M Marty | V Nekljudova | S Paluch-Shimon | D Slamon | C Vogel | S. Johnston | L. Pugliano | F. Penault-Llorca | D. Grun
[1] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[2] J. Mackey,et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Tomasz Burzykowski,et al. Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. , 2009, The Lancet. Oncology.
[4] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[5] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[6] M. Buyse,et al. Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials , 2013, BMJ Open.
[7] Marc Buyse,et al. Surrogate threshold effect: an alternative measure for meta‐analytic surrogate endpoint validation , 2006, Pharmaceutical statistics.
[8] Sung-Bae Kim,et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. , 2013, The Lancet. Oncology.
[9] D. Miles,et al. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] J. Cuzick,et al. Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer , 2008, British Journal of Cancer.
[11] Lyndsay N Harris,et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[13] M. Casey,et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses , 2008, Breast Cancer Research and Treatment.
[14] Marc Buyse,et al. Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission , 2011, Haematologica.
[15] K. Johnson,et al. Is blood pressure reduction a valid surrogate endpoint for stroke prevention? an analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the biomarker-surrogacy (BioSurrogate) evaluation , 2012, BMC Medical Research Methodology.
[16] H. Gómez,et al. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] D. Amadori,et al. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer , 2007, Breast Cancer Research and Treatment.
[18] A. Jemal,et al. Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.
[19] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[20] T. Dobbins,et al. The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] David Grimes,et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Daniel J Sargent,et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Kristine R Broglio,et al. Detecting an overall survival benefit that is derived from progression-free survival. , 2009, Journal of the National Cancer Institute.
[24] N. Coburn,et al. Strategies of sequential therapies in unresectable metastatic colorectal cancer: a meta-analysis. , 2014, Current oncology.
[25] P. Ravdin,et al. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review. , 1995, Gene.
[26] G. Molenberghs,et al. Validation of surrogate end points in multiple randomized clinical trials with failure time end points , 2001 .
[27] R. Gelber,et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial , 2012, The Lancet.
[28] P. Tugwell,et al. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. , 2007, The Journal of rheumatology.
[29] Satoshi Morita,et al. Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. , 2013, Journal of the National Cancer Institute.
[30] D. Sargent,et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] S. Hurvitz,et al. Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential , 2014, Therapeutic advances in medical oncology.
[32] S. Loibl,et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] M. Buyse,et al. Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer. , 2015, Journal of clinical epidemiology.
[34] S. Barni,et al. Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials , 2013, Medical Oncology.
[35] M. Buyse,et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Satoshi Morita,et al. Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. , 2013, Journal of the National Cancer Institute.
[37] P. Barrett-Lee,et al. Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer , 2005, British Journal of Cancer.
[38] H. Gómez,et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] Saeed Sadeghi,et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] J. Baselga,et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.
[41] Caroline Domerg,et al. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data , 2013, The Lancet. Oncology.